These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23408515)

  • 41. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY; Lin TsT; Sung YC; Liu YC; Chiang WH; Chang CC; Liu JY; Chen Y
    Biomaterials; 2015 Oct; 67():194-203. PubMed ID: 26218745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma.
    Lee KK; Kim DG; Moon IS; Lee MD; Park JH
    J Surg Oncol; 2010 Jan; 101(1):47-53. PubMed ID: 19798686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
    Smolle E; Taucher V; Petru E; Haybaeck J
    Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
    Adam R; Azoulay D; Castaing D; Eshkenazy R; Pascal G; Hashizume K; Samuel D; Bismuth H
    Ann Surg; 2003 Oct; 238(4):508-18; discussion 518-9. PubMed ID: 14530722
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors for fatal recurrence of hepatocellular carcinoma and their role in selecting candidates for liver transplantation.
    Zou WL; Zang YJ; Chen XG; Shen ZY
    Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):145-51. PubMed ID: 18397848
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
    Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
    Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
    Shen HJ; Wang YH; Xu J
    Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):98-102. PubMed ID: 23714662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
    Kim MN; Ro SW; Kim DY; Kim da Y; Cho KJ; Park JH; Lim HY; Han KH
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):257-67. PubMed ID: 26037205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of corneal neovascularization in rats by systemic administration of sorafenib.
    Seo JW; Chung SH; Choi JS; Joo CK
    Cornea; 2012 Aug; 31(8):907-12. PubMed ID: 22362003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of sorafenib on murine liver regeneration.
    Hora C; Romanque P; Dufour JF
    Hepatology; 2011 Feb; 53(2):577-86. PubMed ID: 21274878
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
    Groß C; Steiger K; Sayyed S; Heid I; Feuchtinger A; Walch A; Heß J; Unger K; Zitzelsberger H; Settles M; Schlitter AM; Dworniczak J; Altomonte J; Ebert O; Schwaiger M; Rummeny E; Steingötter A; Esposito I; Braren R
    Clin Cancer Res; 2015 Oct; 21(19):4440-50. PubMed ID: 25995341
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence.
    Vivarelli M; Cucchetti A; La Barba G; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Ann Surg; 2008 Nov; 248(5):857-62. PubMed ID: 18948815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis.
    Qin Y; Lu Y; Wang R; Li W; Qu X
    Biosci Trends; 2013 Oct; 7(5):237-44. PubMed ID: 24241174
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
    Leconte M; Santulli P; Chouzenoux S; Marcellin L; Cerles O; Chapron C; Dousset B; Batteux F
    Reprod Sci; 2015 Sep; 22(9):1171-80. PubMed ID: 26169036
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
    Yu W; Gu K; Yu Z; Yuan D; He M; Ma N; Lai S; Zhao J; Ren Z; Zhang X; Shao C; Jiang GL
    Cancer Lett; 2013 Feb; 329(1):109-17. PubMed ID: 23142289
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
    Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
    Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sorafenib prolongs liver regeneration after hepatic resection in rats.
    Mollbrink A; Augsten M; Hultcrantz R; Eriksson LC; Stål P
    J Surg Res; 2013 Oct; 184(2):847-54. PubMed ID: 23726434
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
    Chaparro M; González Moreno L; Trapero-Marugán M; Medina J; Moreno-Otero R
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1269-77. PubMed ID: 18808443
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria.
    Herrero JI; Sangro B; Pardo F; Quiroga J; Iñarrairaegui M; Rotellar F; Montiel C; Alegre F; Prieto J
    Liver Transpl; 2008 Mar; 14(3):272-8. PubMed ID: 18306328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.